Assessment of vaccination coverage in Diabetic patients: analysis of vaccination coverage for pneumococcus and influenza in the population of Azienda Sanitaria Universitaria Friuli Centrale
More details
Hide details
Dipartimento Area Medica, Università degli Studi di Udine, Italy
Dipartimento di Prevenzione Azienda Sanitaria, Universitaria Friuli Centrale, Italy
Publication date: 2023-04-27
Popul. Med. 2023;5(Supplement):A2059
Background and Objective: A diabetic patient has an increased risk of developing invasive infectious diseases caused by micro-organisms such as Influenza Virus and Streptococcus Pneumoniae or serious complications. This risk can be drastically reduced through vaccination. Preventing infectious diseases through vaccinations is a milestone of public health; hence it is essential to investigate vaccination coverage in our target population. The main objective of our study is to analyze the adherence to anti-influenza and anti-pneumococcal vaccinations in the diabetic patient population. Secondly, the coverage of vaccines between age groups was examined with particular attention to completed and partial vaccination courses. Methods: The population was analyzed through the interrogation of the Regional Epidemiological Repository and subsequent analysis. Diabetics residents from 01/01/2002 to 30/04/2022 were studied. Results: The statistical analysis of diabetic patients (32 500 subjects) highlights a full pneumococcal vaccination coverage (sequential schedule) of 16.46%; partial coverage tantamount to 36.75% and 46.79% of patients not vaccinated for Pneumococcus. On the subject of influenza coverage in the target population, we see a complete coverage (annual vaccination carried out) of 47.25%; partial (at least one vaccination from the date of diagnosis) equal to 31.2% and 21.55% of subjects are not vaccinated at all for influenza. It also emerges that 5% of diabetic patients have no known vaccination history in the regional vaccine service. Conclusions: Our analysis underlines that a considerable part of the target population does not have adequate protection from the disease because 83.54% of patients have a partial or absent course against Pneumococcus and 52.75% of cases have a partial or absent course against influenza. Our study will continue by evaluating the impact of COVID-19 pandemic on our target vaccination coverage. In conclusion, it is considered essential to undertake mop-up and catch-up strategies to implement the current coverage in the diabetic population.